Literature DB >> 14639666

Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT.

Walter Pirker1, Iris Holler, Willibald Gerschlager, Susanne Asenbaum, Georg Zettinig, Thomas Brücke.   

Abstract

Recent imaging studies suggest a rapid degeneration of the dopaminergic system in early Parkinson's disease (PD), followed by a slowing of the degenerative process in advanced disease. In the present study, a group of early-stage PD patients underwent three sequential [123I]beta-CIT SPECT studies to assess the decline of striatal dopamine transporter binding over a 5-year period. Twenty-one of a cohort of 24 early PD patients who participated in an earlier longitudinal beta-CIT SPECT imaging study [Mov Disord 2002;17:45-53] were included. Scan intervals were 26 +/- 11 months (scan 1-2) and 38 +/- 15 months (scan 2-3), respectively. The relative annual rate of decline of striatal beta-CIT binding from age-expected normal values at the time of Scan 1 was used as primary outcome variable. The relative annual decline of striatal binding from Scan 1 to Scan 2 (4.5 +/- 4.6%) and from Scan 2 to Scan 3 (3.0 +/- 3.0%) was not significantly different. The non-significant difference in progression rate was due mainly to the rapid early decline of striatal binding in 1 patient who subsequently developed a severe dysexecutive dementia syndrome. These data are not suggestive of substantial change in the course of dopaminergic degeneration in PD within the first 5 to 7 years after symptom onset.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639666     DOI: 10.1002/mds.10531

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Authors:  Hongjun Jin; Xuyi Yue; Hui Liu; Junbin Han; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

2.  Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Authors:  Sean J Colloby; E David Williams; David J Burn; Jim J Lloyd; Ian G McKeith; John T O'Brien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-02       Impact factor: 9.236

3.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

4.  Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.

Authors:  Michael Nocker; Klaus Seppi; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-30       Impact factor: 9.236

5.  GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Authors:  Jay S Schneider; Franca Cambi; Stephen M Gollomp; Hiroto Kuwabara; James R Brašić; Benjamin Leiby; Stephanie Sendek; Dean F Wong
Journal:  J Neurol Sci       Date:  2015-06-16       Impact factor: 3.181

6.  Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts.

Authors:  Oliver Pogarell; Walter Koch; Franz J Gildehaus; Andreas Kupsch; Olle Lindvall; Wolfgang H Oertel; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-27       Impact factor: 9.236

7.  Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Authors:  Chris C Tang; Kathleen L Poston; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

8.  T1rho and T2rho MRI in the evaluation of Parkinson's disease.

Authors:  I Nestrasil; S Michaeli; T Liimatainen; C E Rydeen; C M Kotz; J P Nixon; T Hanson; Paul J Tuite
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

9.  Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.

Authors:  María Sierra; Isabel Martínez-Rodríguez; Pascual Sánchez-Juan; Isabel González-Aramburu; Mikel Jiménez-Alonso; Antonio Sánchez-Rodríguez; José Berciano; Ignacio Banzo; Jon Infante
Journal:  Neurology       Date:  2017-07-05       Impact factor: 9.910

Review 10.  Neuroimaging of Parkinson's disease and atypical parkinsonism.

Authors:  Dennis J Zgaljardic; Andrew Feigin
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.